Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 3

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 3
---
 in any of our securities.

We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more
underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee,
commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled “About this
Prospectus” and “Plan of Distribution” for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.

INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “ RISK FACTORS” ON PAGE 14 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT OR IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.

Our Ordinary Shares are listed on the Nasdaq Global Market under the symbol “CNTB.” On September 9, 2025, the last
reported sale price of our Ordinary Shares on the Nasdaq Global Market was $1.76 per share.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2025.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                 |     |  1 |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS     |     |  2 |
| WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY 
 REFERENCE                                             |     |  3 |
| ENFORCEMENT OF CIVIL LIABILITIES                      |     |  5 |
| THE COMPANY                                           |     |  6 |
| RISK FACTORS                                          |     | 14 |
| USE OF PROCEEDS                                       |     | 15 |
| DESCRIPTION OF SHARE CAPITAL                          |     | 16 |
| DESCRIPTION OF DEBT SECURITIES                        |     | 26 |
| DESCRIPTION OF WARRANTS